IMVTHealthcare · BiotechnologyThe 17 Wall Street analysts covering Immunovant, Inc. hold a median 12-month price target of $49 — +73.8% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 37 of 100 as at 13 Oct 2026 — in the lower half. The Street sees upside; the factor read is a caution. That gap is the story on this page.
Consensus tells you what everyone already believes. The model scores Immunovant, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Momentum (84): The shares have been drifting up relative to others.
Revisions (29): Analysts have, on balance, been cutting their forecasts.
Size (21): Larger than most of the companies we track — more scrutinised, less often mispriced.
Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.
The bullish and bearish analyst opinions on IMVT, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
The green dot is the last close — the median target sits +73.8% from it.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 4 Aug 2026 | JP Morgan | Maintains | Overweight | $47 → $50 |
| 30 June 2026 | Citigroup | Maintains | Buy | $57 → $61 |
| 30 June 2026 | Citigroup | Maintains | Buy | — |
| 26 May 2026 | Guggenheim | Maintains | Buy | — |
| 22 May 2026 | Truist Securities | Maintains | Hold | — |
| 21 May 2026 | B of A Securities | Maintains | Buy | — |
| 21 May 2026 | HC Wainwright & Co. | Maintains | Buy | — |
| 15 Apr 2026 | Goldman Sachs | Maintains | Neutral | — |
| 20 Mar 2026 | Bernstein | Initiates | Market Perform | — |
| 10 Feb 2026 | HC Wainwright & Co. | Reiterates | Buy | — |
| 9 Feb 2026 | Guggenheim | Maintains | Buy | — |
| 8 Jan 2026 | Truist Securities | Maintains | Hold | — |
| 6 Jan 2026 | Wolfe Research | Upgrade | Outperform | — |
| 15 Dec 2025 | Goldman Sachs | Maintains | Neutral | — |
| 14 Oct 2025 | Truist Securities | Initiates | Hold | — |
| 30 Sept 2025 | JP Morgan | Maintains | Overweight | — |
| 4 Sept 2025 | HC Wainwright & Co. | Reiterates | Buy | — |
| 12 Aug 2025 | B of A Securities | Maintains | Buy | — |
| 12 Aug 2025 | JP Morgan | Maintains | Overweight | — |
| 28 July 2025 | UBS | Maintains | Neutral | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. IMVT appears on the weeks it earns a place.
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 14 Oct 2026, Immunovant, Inc. returned +59.5% against +17.5% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 94% of US stocks
Cheaper than 11% of US stocks
Cheaper than 85% of US stocks
Higher than 32% of US stocks
Higher than 30% of US stocks
Higher than 16% of US stocks
Higher than 9% of US stocks
Higher than 1% of US dividend payers
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
Immunovant, Inc. has a market value of $5.8B and an enterprise value of $5.0B.
Revenue in the twelve months to 30 June 2026: $0.0.
Net income over the same four quarters: −$538.2M.
Diluted earnings per share, trailing twelve months: $−2.82.
Free cash flow in the twelve months to 30 June 2026: −$414.3M.
Trailing P/E: −10.1×; forward P/E: −10.1× — the forward figure prices analyst consensus estimates, not reported earnings.
Forward dividend yield: 0.00%, paying out 0% of earnings.
Immunovant, Inc. employs 315 people.
Data provided by Twelve Data
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own Immunovant, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Business Wire reports that SBS Law is offering investors with $100,000 in losses an opportunity to join a fraud investigation involving Immunovant, Inc.
Why it matters — The reported investigation is relevant to IMVT watchers because it concerns allegations involving the company and investors.
SueWallSt has notified investors of a pending investigation into potential securities law violations concerning Immunovant (IMVT). This follows the company's stock falling roughly 6% to a more-than-three-month low on September 23, 2026, after the IMVT-1402 cutaneous lupus study missed its primary endpoint.
Why it matters — IMVT watchers would care because the failed clinical trial outcome, the resulting share-price drop, and the pending securities investigation raise scrutiny around the company's disclosures and its lead drug candidate's prospects.
Immunovant's IMVT-1402 missed its primary endpoint in a cutaneous lupus erythematosus (CLE) trial, leading the company to halt the CLE program despite positive trends and a favorable safety profile. The news weighed on the stock.
Why it matters — The discontinuation of the CLE program removes potential value from Immunovant's pipeline and could raise questions about IMVT-1402's prospects in other indications.
Immunovant reported topline results from the proof-of-concept study of IMVT-1402 (imeroprubart) in cutaneous lupus erythematosus. The study did not achieve statistical significance on its primary endpoint, and while positive trends and favorable safety data were observed, it did not meet Immunovant's internal bar to continue development of IMVT-1402 in CLE. Other clinical development timelines remain on track.
Why it matters — This indicates IMVT-1402 will not be advanced in cutaneous lupus erythematosus, removing a potential indication from Immunovant's pipeline even as other programs continue.
Seeking Alpha published a transcript of Immunovant, Inc.'s Q1 2027 earnings call, covering the company's first-quarter results and management discussion. The item is the call transcript itself rather than an analysis of the results.
Why it matters — An IMVT watcher would care because the earnings call transcript contains the company's own commentary on its quarterly performance and outlook.
The 17 Wall Street analysts covering Immunovant, Inc. have a median 12-month price target of $49, with estimates ranging from $30 to $66. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 17 analysts covering Immunovant, Inc., 13 rate it a Buy, 4 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Immunovant, Inc. 37 out of 100 across roughly 4,600 US stocks as at 13 Oct 2026. None of this is personal advice — it does not consider your circumstances.
As at 13 Oct 2026, Immunovant, Inc. ranks 37 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Momentum (84 of 100).
No one can know that. What the data says: the median 12-month target from 17 analysts implies +73.8% from the last close, and Ticker Nerd's factor model ranks Immunovant, Inc. 37 out of 100 as at 13 Oct 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering Immunovant, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for IMVT are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $30 to $66 over the next 12 months.
Immunovant, Inc. returned +59.5% over the 12 months to 14 Oct 2026, with dividends reinvested. Past performance does not indicate future returns.
Immunovant Inc. is a clinical-stage immunology company focused on developing targeted therapies for autoimmune diseases.
The most recent item we track (Business Wire, 11 Oct 2026): "IMVT Investors with $100,000 in Losses Have Opportunity to Join Immunovant, Inc. Fraud Investigation with SBS Law". Business Wire reports that SBS Law is offering investors with $100,000 in losses an opportunity to join a fraud investigation involving Immunovant, Inc.
Immunovant Inc. is a clinical-stage immunology company focused on developing targeted therapies for autoimmune diseases. The company’s current work centers on antibody-based treatments that inhibit the neonatal Fc receptor, a mechanism designed to lower harmful IgG autoantibodies involved in multiple immune-mediated conditions. Its pipeline includes investigational programs such as IMVT-1402 and batoclimab, which are being studied across diseases including myasthenia gravis, thyroid eye disease, Graves’ disease, chronic inflammatory demyelinating polyneuropathy, rheumatoid arthritis, and related autoimmune disorders. Immunovant Inc. operates within the biopharmaceutical sector and is positioned as a specialist in FcRn-based immunology research, with an emphasis on advancing therapies that address the complex biology of autoimmune disease.
CEO Dr. Eric Venker M.D., Pharm.D. · 315 employees · United States · https://immunovant.com
